Research Supported

 

Eisai products and investigational compounds for which grant requests are currently being evaluated under the IIS program include:

 

Central Nervous System (CNS) & Metabolic 

BANZEL® (rufinamide)

BELVIQ® (lorcaserin HCI) (CIV)

FYCOMPA® (perampanel) tablets

 

Oncology 

HALAVEN® (eribulin mesylate) Injection

LENVIMA® (lenvatinib) capsules


 

Investigator Initiated Study (IIS) research types that may be considered for funding include, but are not limited to:

  •    • Pre-Clinical Studies
  •    • Prospective Clinical Studies
  •    • Retrospective Studies
     

  

Evaluation of Applications

Applications are evaluated based upon therapeutic area relevance and applicability, support of product or compound goals, scientifically compelling and innovative research that is congruent with the strategic focus for the product or compound in question, sound science, cost effectiveness and feasibility of proposal. The IIS Review Committee will also evaluate whether the grant applicant is qualified to receive an IIS research grant based upon the following factors, which include, but are not limited to: appropriate credentials, education, reputation, demonstrable relevant expertise, research background and training (whether clinical or pre-clinical as applicable), knowledge of disease or therapeutic area in which the research will be conducted, valid medical license (if applicable), lack of FDA debarment/disqualification or federal exclusion and disciplinary action by any professional licensing body, ability and potential to successfully conduct the research for which the funds are requested (including staffing and site resources).